false
0001580149
0001580149
2026-11-10
2026-11-10
0001580149
bivi:ClassCommonStockParValue0.0001PerShareMember
2026-11-10
2026-11-10
0001580149
bivi:WarrantsToPurchaseClassCommonStock0.0001ParValuePerShareMember
2026-11-10
2026-11-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November
10, 2026
BioVie Inc.
(Exact name of registrant as specified in its charter)
| Nevada |
|
001-39015 |
|
46-2510769 |
| (State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
680 W. Nye Lane, Suite 201
Carson City, NV |
|
89703 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area
code: (775) 888-3162
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Class A Common Stock, Par Value $0.0001 Per Share |
BIVI |
The Nasdaq Stock Market LLC |
| Warrants to purchase Class A Common Stock, $0.0001 par value per share |
BIVIW |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On November
10, 2026, BioVie Inc. (the “Company”) held its 2026 annual meeting of stockholders
(the “Annual Meeting”). On September 21, 2026, the record date for stockholders entitled to notice of, and to vote
at, the Annual Meeting, 8,682,710 shares of the Company’s Class A common stock (“Common Stock”) were outstanding. The
holders of 4,749,367 shares of Common Stock were present at the Annual Meeting, either virtually or represented by proxy, constituting
a quorum.
The following matters were considered at the Annual
Meeting and the final voting results are set forth below:
| Proposal 1. |
Election of Directors |
Stockholders elected all of the Company’s nominees
for director to hold office until the next annual meeting of stockholders and until their respective successors are elected and qualified.
The voting results were as follows:
| |
|
For |
|
|
Withhold |
|
|
Broker Non-Vote |
|
| (1) AMY CHAPPELL |
|
1,732,353 |
|
|
114,779 |
|
|
2,902,235 |
|
| (2) CUONG DO |
|
1,719,872 |
|
|
127,260 |
|
|
2,902,235 |
|
| (3) KAMEEL FARAG |
|
1,728,973 |
|
|
118,159 |
|
|
2,902,235 |
|
| (4) JAMES LANG |
|
1,729,709 |
|
|
117,423 |
|
|
2,902,235 |
|
| (5) SIGMUND ROGICH |
|
1,728,685 |
|
|
118,447 |
|
|
2,902,235 |
|
| (6) MICHAEL SHERMAN |
|
1,729,940 |
|
|
117,192 |
|
|
2,902,235 |
|
| Proposal 2. |
Ratification of Appointment of Independent Registered Public Accounting Firm |
Stockholders ratified the appointment of EisnerAmper
LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2027. The voting results
were as follows:
| For |
|
Against |
|
Abstain |
|
Broker Non-Vote |
| 4,411,653 |
|
274,205 |
|
63,509 |
|
N/A |
| Proposal 3. |
Amendment and Restatement of the 2019 Omnibus Equity Incentive Plan |
Stockholders approved an amendment and restatement
of the 2019 Omnibus Equity Incentive Plan to increase the number of shares of Common stock available for issuance pursuant to awards granted
thereunder from 399,509 to 3,100,000. The voting results were as follows:
| For |
|
Against |
|
Abstain |
|
Broker Non-Vote |
| 1,020,704 |
|
689,489 |
|
136,939 |
|
2,902,235 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
BioVie INC. |
| |
|
|
| |
By: |
/s/ Joanne Wendy Kim |
| |
|
Name: |
Joanne Wendy Kim |
| |
|
Title: |
Chief Financial Officer |
| |
|
|
|
| Date: November 10, 2026 |
|
|
|